NZ329696A - Use of isolated peptides derived from mage tumour rejection antigen precursors which complex with hla a2 molecules in treating cancer
- Google Patents
Use of isolated peptides derived from mage tumour rejection antigen precursors which complex with hla a2 molecules in treating cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/217,186external-prioritypatent/US5585461A/en
Priority claimed from US08/290,381external-prioritypatent/US5851523A/en
Application filed by Ludwig Inst Cancer Res, Univ Oxford, Univ LeidenfiledCriticalLudwig Inst Cancer Res
Publication of NZ329696ApublicationCriticalpatent/NZ329696A/en
NZ329696A1994-03-241995-03-22Use of isolated peptides derived from mage tumour rejection antigen precursors which complex with hla a2 molecules in treating cancer
NZ329696A
(en)